Morgan Stanley Lifts Biogen Target to $238 but Keeps Equal-Weight
Morgan Stanley raised its Biogen price target to $238 from $231 and kept an Equal-Weight rating, as reported by Dow Jones Newswires citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley increased its price target on Biogen shares to $238 from $231. The bank left its rating on the stock unchanged at Equal-Weight, which means neutral.
The information comes from Dow Jones Newswires, which relayed data from Benzinga's ratings tracker.
why it matters
Target changes from a single analyst like this one usually have a limited effect on the share price, since the rating itself did not change. The signal reflects one brokerage's valuation view rather than a shift across the biotech sector.
tags
instruments
sources
- Biogen Price Target Raised to $238.00/Share From $231.00 by Morgan Stanley — Dow Jones Newswires, 29 October 2026 at 17:39 UTC
- Etsy Price Target Raised to $79.00/Share From $73.00 by Morgan Stanley — Dow Jones Newswires, 29 October 2026 at 17:49 UTC
- Garmin Price Target Raised to $295.00/Share From $289.00 by Morgan Stanley — Dow Jones Newswires, 29 October 2026 at 17:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗